Latest Breaking News On - சர்வதேச பரவல் ப்ரெவெந்ஶந் நடைமேடை - Page 1 : comparemela.com

Among the most promising therapeutic options for individuals with coronavirus disease 2019 (COVID-19) are monoclonal antibodies (mAbs). In this study, Jones et al . identified, characterized, and tested one such mAb, LY-CoV555, in vitro and in vivo. They found that LY-CoV555 bound to the severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) spike protein and prevented its interaction with angiotensin-converting enzyme 2. Prophylactic treatment with LY-CoV555 protected the upper and lower respiratory tracts of nonhuman primates from becoming infected with SARS-CoV-2. Together, these data support the clinical use of LY-CoV555 for treating patients with COVID-19. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) poses a public health threat for which preventive and therapeutic agents are urgently needed. Neutralizing antibodies are a key class of therapeutics that may bridge widespread vaccination campaigns and offer a treatment solution in populations less res

South africaUnited statesUnited kingdomK huntington eli lillyGatan solarusIsoplates perkinelmerEli lillyOxford cryosystemsCarterra epitopeUs department of defenseNational institute of allergyGrossman school of medicine startupLilly research laboratories collaborative access teamBurroughs wellcome fund postdoctoral enrichment program awardUs department of energyInternational patent application no